Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas

The management of transformed indolent lymphomas has evolved in recent years with the inclusion of patients with transformed indolent lymphomas in clinical trials evaluating novel treatment options for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Several novel agents have recently been approved for the treatment of transformed indolent lymphomas. Accurate diagnosis of transformed indolent lymphoma is essential since the prognosis and management is significantly different from that of its indolent counterpart. Treatment should be highly individualized based on histology, prior treatment received for underlying indolent lymphoma, and the patient’s eligibility for transplant. Education about the recent advances and special considerations associated with the diagnosis and management of transformed indolent lymphomas is essential to facilitate the incorporation of novel treatment options into routine clinical practice to improve clinical outcomes.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Outline the current treatment approach for transformed indolent lymphomas.
  • Summarize the evidence from clinical trials supporting the use of CAR T-cell therapy and other novel chemotherapy-free options for the management of transformed indolent lymphomas.
  • Review the unique toxicities associated with novel agents including CAR T-cell therapy and develop an effective supportive care plan for the prevention and management of treatment-related side effects.

You may also be interested in

NCCN Guidelines® Insights - B-Cell Lymphomas, Version 6.2023

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas.
Archived Monthly Oncology Tumor Boards: B-Cell Lymphomas: Histologic Transformation of Indolent Lymphomas
Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.
Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Additional information
Supporters: 

Supported by a grant from Pfizer Inc. Supported by an educational grant from Genentech, a member of the Roche Group. Supported by an independent educational grant from Incyte Corporation. Supported by an independent medical education grant from ADC Therapeutics.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
06/15/2024
Course expires: 
03/01/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Nursing Program: Advancing Oncology Nursing™

Robin R. Klebig, MSN, APRN, AOCNP
Mayo Clinic Comprehensive Cancer Center

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Robin R. Klebig, MSN, APRN, AOCNP
Amanda E. Visnick, RN, BSN, OCN

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.

Available Credit

  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing